Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

OHRP $3.25 0.3000 +10.17%
CELG $104.72 6.3100 +6.41%
BMY $51.96 2.6700 +5.42%
XLRN $28.00 1.0800 +4.01%
UTHR $116.34 3.2600 +2.88%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

AGEN $4.33 -0.9000 -17.21%
SCLN $9.05 -0.8000 -8.12%
KPTI $7.84 -0.5100 -6.11%
IDRA $1.71 -0.1100 -6.04%
BCRX $4.31 -0.2700 -5.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)

(Sirtex) Oct 11, 2016 - Sirtex Medical Limited announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.
read corporate press release 

Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer

(Yahoo! Finance) Oct 12, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that its amended protocol using its NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in ovarian cancer patients with treatment resistant or refractory metastatic ovarian cancer is now actively recruiting.
read article 

Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress

(Daiichi Sankyo) Oct 11, 2016 - Results of first of two-part phase 1 study demonstrate that DS-8201a was well-tolerated with no dose-limiting toxicities; overall preliminary efficacy results report an objective response rate of 35 percent and a disease control rate of 90 percent in HER2 expressing breast and gastric cancer patients; in a subgroup analysis, preliminary efficacy results report an objective response rate of 42 percent and a disease control rate of 92 percent in T-DM1 treated HER2+ breast cancer.
read corporate press release 

Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia

(Daiichi Sankyo) Oct 12, 2016 - No approved targeted therapy exists for FLT3-ITD+ acute myeloid leukemia (AML), an aggressive and difficult-to-treat form of AML affecting approximately 30 percent of AML patients; QuANTUM-First study to examine safety and efficacy of quizartinib as a first-line treatment in combination with induction and consolidation chemotherapy and as maintenance monotherapy in newly-diagnosed patients with FLT3-ITD+ AML.
read corporate press release 

Adding Oxidative Stress to FLT3 Inhibition Proves Promising Combination Against AML

(UCCC/Colorado Cancer Blogs) Oct 11, 2016 - FLT3 inhibitors are a promising new class of drugs targeting acute myeloid leukemia (AML). However, these inhibitors alone tend not to result in long-term control of the disease.
read article 

Bile Duct Study Uncovers Cancer Triggers

(University of Edinburgh [Scotland]) Oct 10, 2016 - Scientists have identified a molecule that drives the development of bile duct cancer.
read article 

Gene That Drives Aggressive Prostate Cancer Identified

(Cornell Chronicle) Oct 10, 2016 - An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease, according to new research at Weill Cornell Medicine.
read article 

Changes in Depression Symptoms Tied to Lung Cancer Survival

(Reuters Health) Oct 12, 2016 - Worsening depression symptoms are associated with shorter survival for lung cancer patients, particularly those in the early stages of disease, according to a new U.S. study.
read article 

Left vs Right Difference in CRC: Now Practice Changing?

(Medscape Medical News) Oct 12, 2016 - Call it the "Left Side Story" or the saga of primary tumor "sidedness" in metastatic colorectal cancer (mCRC).
read article (free registration required) 

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.
read article 

Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients

(Genomic Health) Oct 10, 2016 - Two large international studies underscore ability of Oncotype DX to identify patients with node-positive breast cancer who can forego chemotherapy and its side effects; studies across four countries demonstrate Oncotype DX results significantly change treatment decisions and reduce chemotherapy use.
read corporate press release 

Cancer in Retreat on One Front: Fewer Children Are Dying

(New York Times) Oct 10, 2016 - Deaths from childhood cancer fell 20 percent in the United States from 1999 to 2014. Clinical trials have led to small changes in practice, one expert said.
read article 

FDA Grants Priority Review to Roche's Lucentis for mCNV

(Reuters) Oct 11, 2016 - The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.
read article 

Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt

(Wall Street Journal) Oct 10, 2016 - Alnylam Pharmaceuticals Inc. said a phase 3 trial for one of its drugs would continue, potentially easing investor concerns over the safety of its portfolio.
read article (paid subscription required) 

Theranos Sued by Investor Who Accuses It of Securities Fraud

(New York Times) Oct 10, 2016 - Theranos, the beleaguered Silicon Valley blood-testing company, is being accused of securities fraud by a major investor who has sued contending “myriad deceptions, falsehoods and fraudulent conduct.”
read article 

Hospitals Report Skyrocketing Drug Prices Are Challenging Their Budgets

(Washington Post/Wonkblog) Oct 11, 2016 - A third of hospitals reported that drug price increases had a “severe” effect on their budgets and ability to manage costs in the last two years, according to a new survey funded by organizations that lobby on behalf of hospitals.
read article (free registration required) 

Hillary Said It: Medicare IS A Single-Payer System

(Forbes) Oct 11, 2016 - There was another throwaway line in a presidential debate this week, as there was last time. Last time, Donald Trump spoke it; this time, Hillary did. This one, too, was potentially lost in the haze of puerile posturing in the one corner, and resolute attempts not to throw up in the other.
read article 

CancerLinQ LLC CEO Kevin Fitzpatrick Joins CI4CC Corporate Advisory Board

(ASCO) Oct 10, 2016 - CancerLinQ LLC (CLQ LLC) CEO Kevin Fitzpatrick has been appointed to the Cancer Informatics for Cancer Centers (CI4CC) Corporate Advisory Board.
read press release 

Dr. Nancy Davidson of U Pitt to lead Fred Hutch / University of Washington Cancer Consortium

(Fred Hutch News Service) Oct 10, 2016 - She will serve as bridge builder across treatment, clinical and translational cancer research at Fred Hutch, UW Medicine, Seattle Children’s and Seattle Cancer Care Alliance to work toward ‘a world without cancer’.
read article 

Medivir Focuses Exclusively On Oncology And Reorganizes To Significantly Reduce The Cost Structure

(Medivir) Oct 10, 2016 - Medivir AB today announces a reorganization of the company and a significant cost reduction in both early research and administrative functions.
read corporate press release 

Crescendo Lines Up $790M Takeda Windfall

(Business Weekly [UK]) Oct 10, 2016 - Cambridge UK biopharma business Crescendo Biologics has teed up a potential $790 million milestone bonanza via a collaboration with Japanese pharma giant Takeda.
read article 

IBM Offering U.S. Employees Watson Technology to Identify Cancer Treatments

(Wall Street Journal) Oct 11, 2016 - IBM uses software in several oncology treatment centers globally but says it’s the first time it will be available to U.S. employees.
read article (paid subscription required) 

Most Hospital Palliative-Care Programs Don’t Have Enough Staff

(Washington Post) Oct 10, 2016 - The majority of these programs fail to meet national guidelines for staffing, a recent study found.
read article (free registration required) 

For the Very Ill, Legally Ending Life Is Increasingly Costly

(Reuters Health) Oct 10, 2016 - People with terminal illnesses may legally end their lives with certain medications in the U.S. state of Washington, but researchers report those drugs are getting more and more expensive.
read article 

Is Indication-specific Pricing for Cancer Drugs on the Horizon?

(Cancer Therapy Advisor) Oct 7, 2016 - The clinical benefits of a drug can vary widely among different indications or different patient subpopulations within the same indication.
read article